PF-114 Uses, Dosage, Side Effects and more

PF-114 is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene).

Attribute	Details
Trade Name	PF-114
Generic	PF-114
Type
Formula	C29H27F3N6O
Weight	Average: 532.571 Monoisotopic: 532.219844002
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	January 7, 2025 at 1:49 am

Innovators Monograph